**UNITED STATES**
**SECURITIES AND EXCHANGE COMMISSION**
**Washington, DC 20549**

# FORM 8-K

## CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the**
**Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): January 7, 2016**

**SIENTRA, INC.**
**(Exact Name of Registrant as Specified in Its Charter)**

| Delaware | 001-36709 | 20-5551000 |
|---|---|---|
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

**420 South Fairview Avenue, Suite 200**
**Santa Barbara, CA 93117**
**(Address of Principal Executive Offices and Zip Code)**

**(805) 562-3500**
**(Registrant's Telephone Number, Including Area Code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On January 7, 2016, Sientra, Inc. (the " ***Company*** " or " ***Sientra*** ") sent a letter to surgeons regarding the independent third-party testing of Sientra's products, the submission of such test results to the FDA and other business updates. A copy of the letter is filed as Exhibit 99.1 and is incorporated herein by reference.

***Forward-Looking Statements***

Certain statements incorporated by reference into this Current Report on Form 8-K are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, relating to, among other things, the future performance of Sientra that are based on management's current assumptions and expectations of future events and involve risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding: the results of the independent third-party testing of Sientra's products; Sientra's current inventory supply; and the actions that the FDA may take in response to the results of the independent third-party testing of Sientra's products. Such statements are subject to risks and uncertainties. The Company's business, strategy, operations or financial performance, and actual results may differ materially from those predicted or implied. All statements other than statements of historical fact are forward-looking statements. The words ''believe,'' ''will,'' ''continue,'' ''expect,'' ''plan,'' or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. More information about factors that could cause actual results to differ materially from those incorporated by reference into this Current Report on Form 8-K can be found under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's most recent Quarterly Report on Form 10-Q at http://investors.sientra.com/financial-info/sec-filings/default.aspx or the SEC's website at www.sec.gov. Undue reliance should not be placed on the forward-looking statements incorporated by reference herein, which are based on information available to the Company on the date hereof, and except to the extent required by law, Sientra assumes no obligation to update such statements.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

| Exhibit No. | Description |
|---|---|
| 99.1 | Letter of Sientra, Inc. dated January 7, 2016. |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereto duly authorized.

**SIENTRA, INC.**

Dated: January 7, 2016

By: /s/ Jeffrey Nugent
Jeffrey Nugent
*Chief Executive Officer*

**INDEX TO EXHIBITS**

| Exhibit No. | Description |
|---|---|
| 99.1 | Letter of Sientra, Inc. dated January 7, 2016. |

**Exhibit 99.1**

sientra.

SIMPLICITY IS BEAUTY™

January 7, 2016

Dear Valued Plastic Surgeon,

As an important partner to Sientra, I wanted to reach out to you during my early days as Chairman and CEO to update you on the progress we are making.

Since first joining the Sientra Board of Directors in July 2014, I have had the pleasure of working with Hani Zeini and seeing the Company's growth first hand. Sientra has established a strong reputation for quality, innovation and unparalleled support to our professional partners, and we are working to build on that as we prepare to re-enter the US market as soon as possible.

This role is one I am particularly excited about and prepared for, given my years of experience in the aesthetic space both from a professional and patient/consumer standpoint. My experience in leadership roles at a number of aesthetic medicine, medical device and patient/consumer-focused companies as Chairman, CEO, Director and Founder includes: Precision Dermatology, Revlon, Neutrogena and Bioform, among others. Prior to leading the acquisition and becoming President and CEO of Neutrogena and helping to make it one of the most successful acquisitions in Johnson & Johnson history, I was appointed as Vice President of Global Quality with responsibility for all Johnson & Johnson companies in the pharmaceutical, medical device and consumer sectors reporting directly to the chairman.

Over the last few months, we've been making important progress. In fact, I am very pleased to share with you that the extensive independent, third-party testing of Sientra's products has recently been completed. We have been in continuous communication with the FDA and based on the completion of this testing, we met our stated objective of submitting the data to the FDA prior to the end of 2015. This is an important component of our return-to-market strategy, and we look forward to providing you with further updates as we move forward. In our view, the data has concluded that all Sientra products are safe and represent no significant risk to your patients. This conclusion is supported by a panel of leading board-certified plastic surgeons who reviewed the data, analyses and conclusions prior to submission.

While we have an ample supply of products in inventory to meet your patients' needs, we are also continuing to aggressively develop a variety of alternatives for a high quality, stable manufacturing solution. While we are not yet in a position to provide details or timing of long-term manufacturing or supply scenarios, we are maintaining a strong sense of focus as we diligently work to establish a robust, ongoing source of supply for Sientra's future.

Let me reiterate that all regulatory bodies that have been involved in the Silimed review, including the FDA, have consistently stated that there are no reports of adverse events in connection with this issue and no risks to patient health have been identified . You can remain confident in the safety of Sientra's products.

At Sientra, we remain dedicated to the unparalleled level of service and transparency you expect from us. Our leadership team is laser focused on providing you and your patients with our unique, differentiated products as soon as possible. And finally, we are steadfast in our commitment to board-certified plastic surgeons, and you have my assurance that we will continue to focus on supporting the specialty of plastic surgery.

I am confident that we have a bright future ahead of us. I look forward to communicating with you further in the coming weeks and on a continuing basis as we re-enter the market and regain your high level of confidence and trust in Sientra and our products.

Respectfully,

Jeffrey Nugent
Chairman and Chief Executive Officer
Sientra, Inc.